ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is a 16-week, single center, randomized, double-blind, active-controlled, parallel-group, Phase 3b efficacy and safety study of simultaneous administration of saxagliptin 5 mg plus dapagliflozin 10 mg once daily (QD) compared with dapagliflozin plus placebo for saxagliptin, and placebo for saxagliptin plus placebo for dapagliflozin in patients with Type 2 diabetes who have inadequate glycemic control on metformin or metformin/sulfonylurea.
Epistemonikos ID: 51a6f57f97fda0f98ccc25b31793acaf72f526d0
First added on: May 12, 2024